Lilly said that Effient analysis involved 346 patients with acute coronary syndrome (ACS) who had received either study drug and subsequently underwent isolated CABG at some point during the 15-month TRITON-TIMI 38 trial.
Additionally, to all-cause mortality, this same analysis found that the risk-adjusted rate of cardiovascular death at 30 days was also lower in patients treated with Effient compared with those receiving clopidogrel.
Reportedly, Effient-treated patients experienced a higher volume of chest tube blood loss at 12 hours post-CABG compared to the clopidogrel-treated patients.
Duke University Medical Center Cardiovascular and Thoracic Surgery division chief and lead investigator for the retrospective CABG analysis Peter Smith said that the analysis showed that Effient was associated with a lower mortality rate compared with clopidogrel among these CABG patients but with a significantly higher risk of serious bleeding events.